Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Solid Tumor × Lomustine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Glioblastoma 42 Central Nervous System Neoplasms 21 Brain Neoplasms 21 Glioma 14 Astrocytoma 14 Medulloblastoma 8 Oligodendroglioma 7 Lymphoma 7 Recurrence 6 Neoplasms 6 Gliosarcoma 6 Spinal Cord Neoplasms 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lymphoma, AIDS-Related 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Ependymoma 2 Burkitt Lymphoma 2 Uveal Melanoma 1 Solid Tumor 1 Sarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Optic Nerve Glioma 1 Neuroectodermal Tumors 1 Neoplasms, Plasma Cell 1 Neoplasm Recurrence, Local 1

Interventions

pembrolizumab 11 Injections 11 Paclitaxel 10 Docetaxel 9 Cisplatin 8 Nivolumab 7 Capecitabine 7 Bevacizumab 7 toripalimab 6 senaparib 6 atezolizumab 6 Irinotecan 6 tislelizumab 5 Fluorouracil 5 Cyclophosphamide 5 apatinib 4 Leucovorin 4 Ipilimumab 4 Gemcitabine 4 Fluorodeoxyglucose F18 4 spartalizumab 3 pertuzumab 3 olaparib 3 fludarabine 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Oxaliplatin 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡